Holen Sie sich die Stockscreener-App
20.37
0.20%
-0.04
Handel nachbörslich:
20.30
-0.07
-0.34%
Schlusskurs vom Vortag:
$20.41
Offen:
$20.31
24-Stunden-Volumen:
1.18M
Relative Volume:
0.44
Marktkapitalisierung:
$1.77B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-6.8818
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
+0.25%
1M Leistung:
+21.32%
6M Leistung:
+90.91%
1J Leistung:
+51.22%
1-Tages-Spanne:
$20.00
$20.52
1-Wochen-Bereich:
$19.11
$21.22
52-Wochen-Spanne:
$8.58
$21.22
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
20.37 | 1.77B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals' Revuforj® Recognized as Best New Drug at 2025 Scrip Awards - Quiver Quantitative
(SNDX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Is Syndax Pharmaceuticals Inc 1T3 a good long term investmentCandlestick Pattern Analysis & Rapid Portfolio Expansion - earlytimes.in
Jump Financial LLC Makes New $3.57 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week HighHere's Why - MarketBeat
Syndax Pharmaceuticals (SNDX) Valuation After Strong New Revuforj Data at Major Hematology Meeting - Sahm
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Stempoint Capital LP - MarketBeat
Hsbc Holdings PLC Boosts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research - MarketBeat
SNDX: BTIG Reiterates "Buy" Rating with Price Target of $56 | SN - GuruFocus
TD Cowen reiterates Buy rating on Syndax Pharmaceuticals stock By Investing.com - Investing.com Canada
Should New Revuforj Leukemia Data From ASH 2025 Require Action From Syndax Pharmaceuticals (SNDX) Investors? - Sahm
Syndax Pharmaceuticals (SNDX): Valuation Check After Positive Revuforj Data at the 67th ASH Meeting - Yahoo Finance
Is Syndax Pharmaceuticals Fairly Priced After Recent Oncology Pipeline Momentum? - Yahoo Finance
Transcript : Syndax Pharmaceuticals, Inc. Presents at The 67th American Society of Hematology Annual Meeting, Dec-08-2025 07 - marketscreener.com
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum - The Manila Times
Syndax Pharmaceuticals Highlights Promising Efficacy and Safety Data for Revuforj® at the 67th ASH Annual Meeting - Quiver Quantitative
Schroder Investment Management Group Buys 64,598 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Tema Etfs LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Syndax Pharmaceuticals stock hits 52-week high at 20.25 USD By Investing.com - Investing.com Australia
Saturn V Capital Management LP Sells 540,729 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stonepine Capital Management LLC Buys New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Capital Fund Management S.A. Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Why Syndax Pharmaceuticals Inc. (1T3) stock could rally strongly2025 Macro Impact & Weekly Watchlist for Consistent Profits - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsQuarterly Portfolio Report & Verified Momentum Watchlists - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Is Syndax Pharmaceuticals Inc. (1T3) stock a buy during volatile marketsCPI Data & Safe Capital Growth Tips - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock positioned for digital growth eraWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Syndax Pharmaceuticals (SNDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Syndax Pharmaceuticals Inc a good long term investmentEarnings Growth Projections & Maximize Returns With Insights - earlytimes.in
What insider purchases suggest about Syndax Pharmaceuticals Inc. (1T3) stockMarket Movement Recap & High Accuracy Swing Entry Alerts - Newser
Can Syndax Pharmaceuticals Inc. (1T3) stock reach $200 price targetCEO Change & High Return Trade Opportunity Guides - Newser
CFO Goldan Gifts 1,224 Of Syndax Pharmaceuticals Inc [SNDX] - TradingView
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference - The Manila Times
Geode Capital Management LLC Has $19.20 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Analyst Calls & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Syndax Pharmaceuticals, Inc. $SNDX is Aisling Capital Management LP's 3rd Largest Position - MarketBeat
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha
Syndax Pharmaceuticals, Inc. $SNDX Stock Position Boosted by Franklin Resources Inc. - MarketBeat
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating - MSN
10 Most Promising Stocks with Huge Upside Potential - Insider Monkey
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Rhenman & Partners Asset Management AB - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 10.9% Higher After Analyst Upgrade - MarketBeat
Syndax Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating - MSN
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $35.00 at Barclays - MarketBeat
Barclays Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation - Nasdaq
SNDX Analyst Update: Barclays Raises Price Target to $35 | SNDX Stock News - GuruFocus
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):